<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01587274</url>
  </required_header>
  <id_info>
    <org_study_id>11-10-379</org_study_id>
    <nct_id>NCT01587274</nct_id>
  </id_info>
  <brief_title>A Randomized Study of Three Medication Regimens for Acute Low Back Pain</brief_title>
  <official_title>A Randomized Three-armed Comparative Effectiveness Study of Various Medications for Musculoskeletal Low Back Pain: Defining the Added Benefit of Muscle Relaxants and Opioids.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low back pain causes 2.4% of visits to US emergency departments (ED) resulting in 2.7 million
      visits annually. In a general low back pain (LBP) population, prognosis is poor. About 50% of
      patients who visited general practitioners with new onset musculoskeletal LBP report
      persistent pain and functional disability three months after the index visit. Outcomes are
      similarly poor for the population of patients forced to use an ED for management of their
      LBP. In an observational study of patients with non-traumatic LBP recently completed at the
      PI's institution, patients were contacted one week after ED discharge: 70% reported
      persistent back-pain related functional impairment, 59% reported moderate or severe LBP, and
      69% reported analgesic use within the previous 24 hours. Three months after the ED visit, 48%
      reported functional impairment, 42% reported moderate or severe pain, and 46% reported
      analgesic use within the previous 24 hours.

      A variety of evidence-based medications are available to treat LBP. Non-steroidal
      anti-inflammatory drugs (NSAID) are more efficacious than placebo with regard to pain relief,
      global improvement, and requirement of analgesic medication. Skeletal muscle-relaxants too
      are effective for short-term pain relief and global efficacy. Opioids are commonly used for
      moderate or severe acute LBP,(9) though high-quality evidence supporting this practice is
      lacking.

      Treatment of LBP with multiple concurrent medications is common in the ED setting. Emergency
      physicians often prescribe NSAIDs, skeletal muscle relaxants, and opioids in combination.
      Several clinical trials have compared combination therapy with NSAIDS+ skeletal muscle
      relaxants to monotherapy with just one of these agents. These trials have reported
      heterogeneous results. The combination of opioids + NSAIDS has not been evaluated
      experimentally in patients with acute LBP.

      Given the poor pain and functional outcomes that persist beyond an ED visit for
      musculoskeletal LBP, the investigators propose a clinical trial to evaluate whether combining
      muscle relaxants or opioids with NSAIDs is more effective than NSAID monotherapy for the
      treatment of non-traumatic, non-radicular low back pain. Specifically, the investigators will
      evaluate three distinct hypotheses:

        1. The combination of naproxen + cyclobenzaprine will provide greater relief of LBP than
           naproxen alone seven days after an ED visit, as measured by the Roland Morris low back
           pain functional disability scale

        2. The combination of naproxen + oxycodone/ acetaminophen will provide greater relief of
           LBP than naproxen alone seven days after an ED visit, as measured by the Roland Morris
           low back pain functional disability scale

        3. The combination of naproxen + oxycodone/ acetaminophen will provide greater relief of
           LBP than naproxen + cyclobenzaprine seven days after an ED visit, as measured by the
           Roland Morris low back pain functional disability scale
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Functional Disability as Measured by the Roland Morris Disability Questionnaire</measure>
    <time_frame>Baseline and one week after discharge from emergency department</time_frame>
    <description>The Roland Morris Disability Questionnaire (RMDQ) is a 24 item instrument that evaluates the impact of low back pain on one's daily life. It is most sensitive for patients with mild to moderate disability due to acute, sub-acute or chronic low back pain. Each question can be answered as either a &quot;yes&quot; or &quot;no&quot;. The score ranges from 0 to 24 where a higher score reflects greater impairment and, therefore, worsening in the quality of life. The change in RMDQ is obtained by subtracting the RMDQ score at one week after discharge from the baseline score.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">323</enrollment>
  <condition>Acute Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Opioid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naproxen + opioid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Skeletal muscle relaxant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naproxen + skeletal muscle relaxant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naproxen + placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Naproxen 500mg twice/ day x 10 days</description>
    <arm_group_label>Naproxen alone</arm_group_label>
    <arm_group_label>Opioid</arm_group_label>
    <arm_group_label>Skeletal muscle relaxant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclobenzaprine</intervention_name>
    <description>Cyclobenzaprine 5-10mg three times/ day x 10 days</description>
    <arm_group_label>Skeletal muscle relaxant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone/ acetaminophen</intervention_name>
    <description>Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days</description>
    <arm_group_label>Opioid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-radicular, non-traumatic low back pain of no more than 2 weeks duration

        Exclusion Criteria:

          -  Back pain longer than 2 weeks

          -  Prior to the acute attack of low back pain, back pain once per month or more
             frequently

          -  Prior to the acute attack of low back pain, daily or near daily use of pain medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 26, 2012</study_first_submitted>
  <study_first_submitted_qc>April 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2012</study_first_posted>
  <results_first_submitted>April 15, 2018</results_first_submitted>
  <results_first_submitted_qc>July 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2018</results_first_posted>
  <last_update_submitted>July 4, 2018</last_update_submitted>
  <last_update_submitted_qc>July 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin W. Friedman, MD</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>low back pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Cyclobenzaprine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Opioid</title>
          <description>Naproxen + opioid
Naproxen: Naproxen 500mg twice/ day x 10 days
Oxycodone/ acetaminophen: Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days</description>
        </group>
        <group group_id="P2">
          <title>Skeletal Muscle Relaxant</title>
          <description>Naproxen + skeletal muscle relaxant
Naproxen: Naproxen 500mg twice/ day x 10 days
Cyclobenzaprine: Cyclobenzaprine 5-10mg three times/ day x 10 days</description>
        </group>
        <group group_id="P3">
          <title>Naproxen Alone</title>
          <description>Naproxen + placebo
Naproxen: Naproxen 500mg twice/ day x 10 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients enrolled and randomized</population>
      <group_list>
        <group group_id="B1">
          <title>Opioid</title>
          <description>Naproxen + opioid
Naproxen: Naproxen 500mg twice/ day x 10 days
Oxycodone/ acetaminophen: Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days</description>
        </group>
        <group group_id="B2">
          <title>Skeletal Muscle Relaxant</title>
          <description>Naproxen + skeletal muscle relaxant
Naproxen: Naproxen 500mg twice/ day x 10 days
Cyclobenzaprine: Cyclobenzaprine 5-10mg three times/ day x 10 days</description>
        </group>
        <group group_id="B3">
          <title>Naproxen Alone</title>
          <description>Naproxen + placebo
Naproxen: Naproxen 500mg twice/ day x 10 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="108"/>
            <count group_id="B2" value="108"/>
            <count group_id="B3" value="107"/>
            <count group_id="B4" value="323"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="108"/>
                    <count group_id="B3" value="107"/>
                    <count group_id="B4" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="11"/>
                    <measurement group_id="B2" value="38" spread="11"/>
                    <measurement group_id="B3" value="39" spread="11"/>
                    <measurement group_id="B4" value="39" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="108"/>
                    <count group_id="B3" value="107"/>
                    <count group_id="B4" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="108"/>
                    <count group_id="B3" value="107"/>
                    <count group_id="B4" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-existing functional impairment as measured by the Roland Morris Disability Questionnaire</title>
          <description>The Roland Morris Disability Questionnaire (RMDQ) is a 24 item instrument that evaluates the impact of low back pain on one's daily life. It is most sensitive for patients with mild to moderate disability due to acute, sub-acute or chronic low back pain. Each question can be answered as either a &quot;yes&quot; or &quot;no&quot;. The score ranges from 0 to 24 where a higher score reflects greater impairment and, therefore, worsening in the quality of life.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="108"/>
                    <count group_id="B3" value="107"/>
                    <count group_id="B4" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="17" upper_limit="22"/>
                    <measurement group_id="B2" value="19" lower_limit="17" upper_limit="21"/>
                    <measurement group_id="B3" value="20" lower_limit="17" upper_limit="21"/>
                    <measurement group_id="B4" value="20" lower_limit="17" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Functional Disability as Measured by the Roland Morris Disability Questionnaire</title>
        <description>The Roland Morris Disability Questionnaire (RMDQ) is a 24 item instrument that evaluates the impact of low back pain on one's daily life. It is most sensitive for patients with mild to moderate disability due to acute, sub-acute or chronic low back pain. Each question can be answered as either a &quot;yes&quot; or &quot;no&quot;. The score ranges from 0 to 24 where a higher score reflects greater impairment and, therefore, worsening in the quality of life. The change in RMDQ is obtained by subtracting the RMDQ score at one week after discharge from the baseline score.</description>
        <time_frame>Baseline and one week after discharge from emergency department</time_frame>
        <population>Multiple imputation used to account for participants lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Opioid</title>
            <description>Naproxen + opioid
Naproxen: Naproxen 500mg twice/ day x 10 days
Oxycodone/ acetaminophen: Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days</description>
          </group>
          <group group_id="O2">
            <title>Skeletal Muscle Relaxant</title>
            <description>Naproxen + skeletal muscle relaxant
Naproxen: Naproxen 500mg twice/ day x 10 days
Cyclobenzaprine: Cyclobenzaprine 5-10mg three times/ day x 10 days</description>
          </group>
          <group group_id="O3">
            <title>Naproxen Alone</title>
            <description>Naproxen + placebo
Naproxen: Naproxen 500mg twice/ day x 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Disability as Measured by the Roland Morris Disability Questionnaire</title>
          <description>The Roland Morris Disability Questionnaire (RMDQ) is a 24 item instrument that evaluates the impact of low back pain on one's daily life. It is most sensitive for patients with mild to moderate disability due to acute, sub-acute or chronic low back pain. Each question can be answered as either a &quot;yes&quot; or &quot;no&quot;. The score ranges from 0 to 24 where a higher score reflects greater impairment and, therefore, worsening in the quality of life. The change in RMDQ is obtained by subtracting the RMDQ score at one week after discharge from the baseline score.</description>
          <population>Multiple imputation used to account for participants lost to follow-up</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="15"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="16"/>
                    <measurement group_id="O3" value="7" lower_limit="0" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Opioid</title>
          <description>Naproxen + opioid
Naproxen: Naproxen 500mg twice/ day x 10 days
Oxycodone/ acetaminophen: Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days</description>
        </group>
        <group group_id="E2">
          <title>Skeletal Muscle Relaxant</title>
          <description>Naproxen + skeletal muscle relaxant
Naproxen: Naproxen 500mg twice/ day x 10 days
Cyclobenzaprine: Cyclobenzaprine 5-10mg three times/ day x 10 days</description>
        </group>
        <group group_id="E3">
          <title>Naproxen Alone</title>
          <description>Naproxen + placebo
Naproxen: Naproxen 500mg twice/ day x 10 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/ vomiting</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Stomach irritation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benjamin W. Friedman, MD</name_or_title>
      <organization>Montefiore Health</organization>
      <phone>7189206626</phone>
      <email>befriedm@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

